Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has announced its plans to unveil the financial results for the first quarter of 2024 on Wednesday, May 8, 2024, at 7:00 a.m. ET through a press release. Subsequent to the release, Teva will host a conference call and live webcast on the same day at 8:00 a.m. ET.
To participate in the event, interested parties are encouraged to register in advance to receive access to a local or toll-free phone number along with a personal pin. The registration link can be found here.
A live webcast of the conference call will be accessible on Teva’s website at https://ir.tevapharm.com/Events-and-Presentations. Additionally, within 24 hours after the call concludes, a replay of the webcast will be made available on Teva’s website.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a prominent global pharmaceutical leader renowned for its diverse portfolio, combining generics expertise with innovative strides to advance the discovery, delivery, and expanded development of modern medicine. With a legacy spanning over 120 years, Teva remains steadfast in its commitment to enhancing health outcomes. The company’s extensive global network empowers its 37,000 employees across 58 markets to pioneer scientific innovation and provide quality medicines, benefiting millions of patients worldwide. For further insights into Teva’s dedication to better health, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements:
This document and the associated conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current beliefs and expectations and are subject to significant risks and uncertainties, known and unknown, which could cause future results, performance, or achievements to differ materially from those expressed or implied. Important factors contributing to such differences may include risks related to market competition, substantial indebtedness, general business and operational challenges, regulatory and litigation matters, financial and economic risks, and other factors detailed in this press release and in Teva’s Annual Report on Form 10-K for the year ended December 31, 2023, particularly in the sections titled “Risk Factors.” Forward-looking statements speak only as of their date of origin, and Teva assumes no obligation to update or revise any forward-looking statements or other information contained herein, whether due to new information, future events, or otherwise. Readers are cautioned against placing undue reliance on these forward-looking statements.
